Does the media favor ALUR or NSPR?

In the previous week, InspireMD had 3 more articles in the media than Allurion Technologies. MarketBeat recorded 4 mentions for InspireMD and 1 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 1.42 beat InspireMD's score of 0.72 indicating that Allurion Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allurion Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InspireMD 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ALUR or NTRB?

Allurion Technologies presently has a consensus target price of $3.00, indicating a potential upside of 322.36%. Given Allurion Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe Allurion Technologies is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer STRR or ALUR?

In the previous week, Star Equity had 13 more articles in the media than Allurion Technologies. MarketBeat recorded 14 mentions for Star Equity and 1 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 1.42 beat Star Equity's score of 1.20 indicating that Allurion Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Star Equity 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allurion Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Allurion Technologies (ALUR) Competitors

$0.71 -0.02 (-2.62%)

As of 12:21 PM Eastern

Compare

ALUR vs. PSTV, NSPR, NTRB, STRR, and TELA

Should you buy Allurion Technologies stock or one of its competitors? MarketBeat compares Allurion Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allurion Technologies include Plus Therapeutics (PSTV), InspireMD (NSPR), Nutriband (NTRB), Star Equity (STRR), and TELA Bio (TELA). These companies are all part of the "medical equipment" industry.

How does Allurion Technologies compare to Plus Therapeutics?

Allurion Technologies (NYSE:ALUR) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Allurion Technologies and Allurion Technologies both had 1 articles in the media. Allurion Technologies' average media sentiment score of 1.42 beat Plus Therapeutics' score of 1.27 indicating that Allurion Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Allurion Technologies	Positive
Plus Therapeutics	Positive

Allurion Technologies presently has a consensus target price of $3.00, indicating a potential upside of 322.36%. Plus Therapeutics has a consensus target price of $58.00, indicating a potential upside of 978.07%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Allurion Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Allurion Technologies has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.62	-$7.20M	-$1.75	N/A
Plus Therapeutics	$5.21M	7.10	-$22.39M	-$2.30	N/A

Allurion Technologies has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

Allurion Technologies has a net margin of -199.96% compared to Plus Therapeutics' net margin of -230.24%. Allurion Technologies' return on equity of 0.00% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Summary

Allurion Technologies beats Plus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Allurion Technologies compare to InspireMD?

Allurion Technologies (NYSE:ALUR) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

In the previous week, InspireMD had 3 more articles in the media than Allurion Technologies. MarketBeat recorded 4 mentions for InspireMD and 1 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 1.42 beat InspireMD's score of 0.72 indicating that Allurion Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allurion Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InspireMD	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allurion Technologies currently has a consensus target price of $3.00, suggesting a potential upside of 322.36%. InspireMD has a consensus target price of $4.50, suggesting a potential upside of 341.22%. Given InspireMD's stronger consensus rating and higher possible upside, analysts clearly believe InspireMD is more favorable than Allurion Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Allurion Technologies has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.62	-$7.20M	-$1.75	N/A
InspireMD	$10.85M	4.40	-$19.92M	-$0.73	N/A

Allurion Technologies has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market. Comparatively, InspireMD has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 8.1% of Allurion Technologies shares are owned by insiders. Comparatively, 29.7% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Allurion Technologies has a net margin of -199.96% compared to InspireMD's net margin of -413.96%. Allurion Technologies' return on equity of 0.00% beat InspireMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
InspireMD	-413.96%	-69.42%	-57.68%

Summary

InspireMD beats Allurion Technologies on 10 of the 16 factors compared between the two stocks.

How does Allurion Technologies compare to Nutriband?

Allurion Technologies (NYSE:ALUR) and Nutriband (NASDAQ:NTRB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 19.7% of Nutriband shares are owned by institutional investors. 8.1% of Allurion Technologies shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Allurion Technologies and Allurion Technologies both had 1 articles in the media. Allurion Technologies' average media sentiment score of 1.42 beat Nutriband's score of 0.93 indicating that Allurion Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Allurion Technologies	Positive
Nutriband	Positive

Allurion Technologies has higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.62	-$7.20M	-$1.75	N/A
Nutriband	$2.04M	20.74	-$8.23M	-$2.60	N/A

Allurion Technologies presently has a consensus target price of $3.00, indicating a potential upside of 322.36%. Given Allurion Technologies' stronger consensus rating and higher probable upside, research analysts plainly believe Allurion Technologies is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Allurion Technologies has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market. Comparatively, Nutriband has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Allurion Technologies has a net margin of -199.96% compared to Nutriband's net margin of -403.98%. Allurion Technologies' return on equity of 0.00% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
Nutriband	-403.98%	-118.33%	-101.92%

Summary

Allurion Technologies beats Nutriband on 12 of the 15 factors compared between the two stocks.

How does Allurion Technologies compare to Star Equity?

Star Equity (NASDAQ:STRR) and Allurion Technologies (NYSE:ALUR) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Star Equity has higher revenue and earnings than Allurion Technologies. Star Equity is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Star Equity	$172.16M	0.25	-$5.92M	-$2.63	N/A
Allurion Technologies	$17.21M	0.62	-$7.20M	-$1.75	N/A

Star Equity presently has a consensus price target of $28.00, suggesting a potential upside of 141.38%. Allurion Technologies has a consensus price target of $3.00, suggesting a potential upside of 322.36%. Given Allurion Technologies' higher possible upside, analysts clearly believe Allurion Technologies is more favorable than Star Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Star Equity	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Star Equity has a net margin of -4.18% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat Star Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Star Equity	-4.18%	-4.04%	-2.40%
Allurion Technologies	-199.96%	N/A	-77.13%

In the previous week, Star Equity had 13 more articles in the media than Allurion Technologies. MarketBeat recorded 14 mentions for Star Equity and 1 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 1.42 beat Star Equity's score of 1.20 indicating that Allurion Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Star Equity	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allurion Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.8% of Star Equity shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 10.4% of Star Equity shares are held by insiders. Comparatively, 8.1% of Allurion Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Star Equity has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market.

Summary

Star Equity beats Allurion Technologies on 9 of the 16 factors compared between the two stocks.

How does Allurion Technologies compare to TELA Bio?

TELA Bio (NASDAQ:TELA) and Allurion Technologies (NYSE:ALUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Allurion Technologies has lower revenue, but higher earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.50	-$38.83M	-$0.79	N/A
Allurion Technologies	$17.21M	0.62	-$7.20M	-$1.75	N/A

TELA Bio has a net margin of -49.30% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-49.30%	-1,320.81%	-55.83%
Allurion Technologies	-199.96%	N/A	-77.13%

In the previous week, TELA Bio had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for TELA Bio and 1 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 1.42 beat TELA Bio's score of 0.94 indicating that Allurion Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
TELA Bio	Positive
Allurion Technologies	Positive

TELA Bio has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Allurion Technologies has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market.

TELA Bio presently has a consensus target price of $2.20, suggesting a potential upside of 144.25%. Allurion Technologies has a consensus target price of $3.00, suggesting a potential upside of 322.36%. Given Allurion Technologies' higher probable upside, analysts plainly believe Allurion Technologies is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

94.4% of TELA Bio shares are owned by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are owned by institutional investors. 4.7% of TELA Bio shares are owned by insiders. Comparatively, 8.1% of Allurion Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

TELA Bio beats Allurion Technologies on 9 of the 16 factors compared between the two stocks.

Get Allurion Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALUR vs. The Competition

Export

Metric	Allurion Technologies	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$10.65M	$7.92B	$6.26B	$23.11B
Dividend Yield	N/A	2.56%	2.69%	4.09%
P/E Ratio	-0.07	15.35	22.37	31.03
Price / Sales	0.62	5.67	547.57	14.71
Price / Cash	N/A	17.23	42.31	24.78
Price / Book	-0.02	3.52	9.79	4.68
Net Income	-$7.20M	$224.05M	$3.56B	$1.07B
7 Day Performance	-11.21%	-1.47%	-1.27%	-0.50%
1 Month Performance	1.47%	0.00%	3.58%	0.39%
1 Year Performance	-75.25%	-0.20%	27.13%	25.64%

Allurion Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALUR Allurion Technologies	1.8166 of 5 stars	$0.71 -2.6%	$3.00 +322.4%	-73.5%	$10.65M	$17.21M	N/A	501	News Coverage Positive News Gap Up
PSTV Plus Therapeutics	2.9279 of 5 stars	$6.60 +0.2%	$58.00 +778.8%	-40.5%	$45.36M	$5.21M	N/A	20	Positive News
NSPR InspireMD	4.1358 of 5 stars	$0.95 -5.0%	$4.50 +373.7%	-60.2%	$44.50M	$10.85M	N/A	50
NTRB Nutriband	0.69 of 5 stars	$3.48 -4.4%	N/A	-56.2%	$44.25M	$2.04M	N/A	10	High Trading Volume
STRR Star Equity	4.2994 of 5 stars	$11.55 +0.6%	$28.00 +142.4%	+334.1%	$42.43M	$172.16M	N/A	1,200	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ALUR) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allurion Technologies (ALUR) Competitors

ALUR vs. PSTV, NSPR, NTRB, STRR, and TELA

How does Allurion Technologies compare to Plus Therapeutics?

Summary

How does Allurion Technologies compare to InspireMD?

Summary

How does Allurion Technologies compare to Nutriband?

Summary

How does Allurion Technologies compare to Star Equity?

Summary

How does Allurion Technologies compare to TELA Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALUR vs. The Competition

Allurion Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allurion Technologies (ALUR) Competitors

ALUR vs. PSTV, NSPR, NTRB, STRR, and TELA

How does Allurion Technologies compare to Plus Therapeutics?

Do institutionals & insiders have more ownership in ALUR or PSTV?

Does the media favor ALUR or PSTV?

Do analysts recommend ALUR or PSTV?

Which has stronger valuation and earnings, ALUR or PSTV?

Which has more risk and volatility, ALUR or PSTV?

Is ALUR or PSTV more profitable?

Summary

How does Allurion Technologies compare to InspireMD?

Does the media favor ALUR or NSPR?

Do analysts prefer ALUR or NSPR?

Which has preferable earnings and valuation, ALUR or NSPR?

Which has more volatility and risk, ALUR or NSPR?

Do institutionals & insiders have more ownership in ALUR or NSPR?

Is ALUR or NSPR more profitable?

Summary

How does Allurion Technologies compare to Nutriband?

Do institutionals & insiders have more ownership in ALUR or NTRB?

Does the media favor ALUR or NTRB?

Which has stronger earnings and valuation, ALUR or NTRB?

Do analysts prefer ALUR or NTRB?

Which has more risk & volatility, ALUR or NTRB?

Is ALUR or NTRB more profitable?

Summary

How does Allurion Technologies compare to Star Equity?

Which has higher earnings and valuation, STRR or ALUR?

Do analysts recommend STRR or ALUR?

Is STRR or ALUR more profitable?

Does the media prefer STRR or ALUR?

Do institutionals & insiders hold more shares of STRR or ALUR?

Which has more volatility & risk, STRR or ALUR?

Summary

How does Allurion Technologies compare to TELA Bio?

Which has higher earnings and valuation, TELA or ALUR?

Is TELA or ALUR more profitable?

Does the media favor TELA or ALUR?

Which has more volatility and risk, TELA or ALUR?

Do analysts prefer TELA or ALUR?

Do institutionals and insiders hold more shares of TELA or ALUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALUR vs. The Competition

Allurion Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools